Asset profile

guselkumab · Tremfya

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved — Psoriasis, Crohn's Disease, Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

Also in development:Atopic Dermatitis

How the evidence outlook works ↗

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
October 2026 (1)
Phase 3Psoriatic ArthritisRecruiting
Est. primary completion 2026-10 · NCT05669833 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (4)
February 2027 (1)
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-02-10 · NCT06260163 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2027-03-25 · NCT05347095 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2027-06-08 · NCT06408935 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-10-27 · NCT05923073 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (2)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2028-11-15 · NCT07499232 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)
December 2031 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2031-12-12 · NCT06663332 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.